DENTSPLY SIRONA (XRAY) AI Stock Analysis

• Market Cap: $3.17B
• Dividend Yield: 4.02%
• Average Volume (3M): 2.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.45
• Revenue Growth: -5.61%
• EPS Growth: -921.99%
• Country: US
• Employees: 14,000
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.43
• Shares Outstanding: 199,293,380
• 10 Day Avg. Volume: 2,291,040
• 30 Day Avg. Volume: 2,199,705
• PEG Ratio: -15.32
• Price to Book (P/B): 1.52
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 11.01
• Enterprise Value/Market Cap: 1.60
• Enterprise Value/Revenue: 0.33
• Enterprise Value/Gross Profit: 2.65
• Enterprise Value/Ebitda: -7.31
• 1Y Price Target: $17.75
• Price Target Upside: 11.42% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 12

• Rating: 60 Neutral
• Price Target: $17.00 ▲(6.72%Upside)

The overall stock score reflects a challenging financial performance with declining revenues and profitability, but is supported by positive technical indicators and strategic corporate actions. While valuation remains a concern due to negative earnings, the dividend yield and successful debt management provide some reassurance. Corporate events, such as the appointment of a new CFO, signal potential for future improvement.

Positive Factors

Earnings

Adjusted EPS of $0.43 easily beat the estimate of $0.28 as well as the consensus estimate of $0.30.

Financial Performance

Dentsply Sirona generated $879 million in net sales versus the estimate of $863 million, exceeding expectations.

Negative Factors

Executive Turnover

XRAY has experienced significant executive turnover over the last several years, and the lack of permanent CFO amidst a multitude of strategic changes, restructuring efforts, and ERP implementation has not been ideal.

Market Environment

There are outstanding questions about XRAY's ability to drive topline growth in a challenging market environment.

DENTSPLY SIRONA Business Overview & Revenue Model

Company Description

DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide. The company operates through two segments, Technologies & Equipment, and Consumables. The Technologies & Equipment segment provides dental equipment, such as treatment centers, imaging equipment, motorized dental handpieces, and other instruments for dental practitioners and specialists; dental CAD/CAM technologies for dental offices to support various digital dental procedures, including dental restorations; dentist-directed clear aligner solutions, SureSmile, and direct-to-consumer clear aligner solutions, as well as high frequency vibration technology device; implants; and urology catheters and other healthcare-related consumable products. The Consumables segment offers endodontic products comprising drills, filers, sealers, irrigation needles, and other tools or single-use solutions, which support root canal procedures; restorative products that include artificial teeth, dental ceramics, digital dentures, precious metal dental alloys, and crown and bridge porcelain products. It also provides small equipment products, which comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers, as well as dental anesthetics, prophylaxis paste, dental sealants, impression materials, teeth whiteners, and topical fluoride. The company was founded in 1877 and is headquartered in Charlotte, North Carolina.

How the Company Makes Money

DENTSPLY SIRONA generates revenue primarily through the sale of its dental products and technologies. This includes a wide range of dental equipment such as imaging systems, treatment centers, and instruments, as well as consumables like dental implants, orthodontic products, and restorative materials. The company also earns from providing repair and maintenance services for its equipment. Key revenue streams include direct sales to dental professionals and partnerships with dental distributors globally. Strategic alliances and collaborations with dental associations and educational institutions further enhance its market reach and contribute to its revenue.

DENTSPLY SIRONA Financial Statement Overview

Summary

DENTSPLY SIRONA faces financial difficulties with declining revenues and profitability, as evidenced by negative margins and net losses. The balance sheet demonstrates moderate leverage and equity stability, but the negative ROE raises concerns about shareholder value. Cash flow management remains a relative strength, providing some stability amidst operational challenges.

Income Statement

The income statement shows declining revenue and profitability. The TTM (Trailing-Twelve-Months) data indicates a negative net profit margin of approximately -24.4% and a gross profit margin of 51.6%. The company has experienced a negative revenue growth rate of -0.5% compared to the previous year. EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The balance sheet reflects moderate stability with a debt-to-equity ratio of 1.2, indicating a balanced leverage. The equity ratio stands at approximately 33.2%, showing a reasonable proportion of equity financing. Return on Equity (ROE) is negative due to recent losses, which is a concern for potential investors.

Cash Flow

Cash flow analysis shows positive operating cash flow with an operating cash flow to net income ratio of approximately -0.49, indicating operating efficiencies despite net losses. Free cash flow growth rate is slightly negative, but free cash flow to net income ratio is positive, suggesting effective cash management relative to earnings challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.72B	3.79B	3.96B	3.92B	4.25B	3.34B
Gross Profit	1.92B	1.96B	2.09B	2.13B	2.36B	1.66B
EBITDA	-576.00M	-532.00M	232.00M	-677.00M	972.00M	336.00M
Net Income	-908.00M	-910.00M	-132.00M	-950.00M	411.00M	-83.00M
Balance Sheet
Total Assets	6.05B	5.75B	7.37B	7.64B	9.22B	9.34B
Cash, Cash Equivalents and Short-Term Investments	398.00M	272.00M	334.00M	365.00M	339.00M	438.00M
Total Debt	2.42B	2.27B	2.30B	2.09B	2.24B	2.41B
Total Liabilities	4.04B	3.81B	4.08B	3.83B	4.18B	4.37B
Stockholders Equity	2.01B	1.94B	3.29B	3.81B	5.04B	4.97B
Cash Flow
Free Cash Flow	278.00M	281.00M	228.00M	368.00M	515.00M	548.00M
Operating Cash Flow	443.00M	461.00M	377.00M	517.00M	657.00M	635.00M
Investing Cash Flow	-171.00M	-197.00M	-89.00M	-138.00M	-358.00M	-1.11B
Financing Cash Flow	-165.00M	-302.00M	-307.00M	-329.00M	-379.00M	490.00M

DENTSPLY SIRONA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.93
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRAY, the sentiment is Positive. The current price of 15.93 is above the 20-day moving average (MA) of 15.69, above the 50-day MA of 15.13, and below the 200-day MA of 18.20, indicating a neutral trend. The MACD of 0.07 indicates Positive momentum. The RSI at 55.73 is Neutral, neither overbought nor oversold. The STOCH value of 73.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XRAY.

DENTSPLY SIRONA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RMD	85 Outperform	$37.41B	28.65	25.81%	0.83%	9.54%	37.23%
HOLX	70 Outperform	$14.49B	27.45	11.77%	―	1.66%	21.95%
COO	69 Neutral	$14.19B	34.51	5.15%	―	6.88%	21.11%
BDX	68 Neutral	$48.97B	32.60	5.97%	2.43%	5.84%	15.12%
XRAY	60 Neutral	$3.17B	―	-34.47%	4.02%	-5.61%	-921.99%
BAX	60 Neutral	$15.60B	136.07	-8.96%	2.24%	-20.17%	-138.32%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.33%	16.99%	1.69%

DENTSPLY SIRONA Corporate Events

DENTSPLY SIRONA Issues $550M Junior Subordinated Notes

On June 12, 2025, DENTSPLY SIRONA Inc. issued $550 million in Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2055, with an interest rate of 8.375% per year until 2030, and thereafter adjusted based on the Five-year U.S. Treasury Rate plus a spread, ensuring it does not fall below the initial rate. The proceeds from this issuance were partially used to repay and terminate the company’s $435 million Bridge Loan Facility, resulting in no early termination penalties or prepayment premiums, which may positively impact the company’s financial stability and operational flexibility.

The most recent analyst rating on (XRAY) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

Dentsply Sirona Announces $550 Million Notes Offering

On June 5, 2025, Dentsply Sirona Inc. announced it had entered into an Underwriting Agreement with Goldman Sachs & Co. LLC to issue and sell $550 million of its 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2055. The net proceeds of approximately $544.5 million from this offering will be used for general corporate purposes, including repaying existing indebtedness. The offering is expected to close on June 12, 2025, subject to customary closing conditions, and is part of the company’s strategy to manage its financial obligations effectively.

The most recent analyst rating on (XRAY) stock is a Hold with a $23.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

DENTSPLY SIRONA Amends Credit Facility for Flexibility

On June 3, 2025, DENTSPLY SIRONA Inc. secured consent from its lenders to amend its revolving credit facility and entered into several agreements to adjust financial covenants and debt management strategies. These amendments, including a new financial covenant and leverage ratio adjustments, aim to enhance financial flexibility and manage interest rate risks, potentially impacting the company’s financial operations and stakeholder interests.

The most recent analyst rating on (XRAY) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

Dentsply Sirona Appoints New CFO Matthew E. Garth

On May 27, 2025, Dentsply Sirona announced the appointment of Matthew E. Garth as Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of financial management experience, having previously served in senior roles at The Scotts Miracle-Gro Company and Minerals Technologies Inc. His appointment is seen as a strategic move to drive Dentsply Sirona’s transformational journey and enhance shareholder value, with a focus on advancing the company’s financial, operational, and strategic goals.

The most recent analyst rating on (XRAY) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

DENTSPLY SIRONA Holds Annual Stockholder Meeting

On May 21, 2025, DENTSPLY SIRONA held its annual meeting of stockholders where several key decisions were made. These included the election of eleven directors, the ratification of Deloitte and Touche LLP as the company’s independent accountants for 2025, approval of executive compensation for 2024, and an amendment to increase shares under the 2024 Omnibus Incentive Plan. These decisions reflect the company’s ongoing governance and strategic planning efforts.

The most recent analyst rating on (XRAY) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on DENTSPLY SIRONA stock, see the XRAY Stock Forecast page.

Dentsply Sirona CEO Takes on Interim CFO Role

On May 8, 2025, Dentsply Sirona announced that Herman V. Cueto completed his role as interim CFO, with CEO Simon D. Campion temporarily assuming the financial officer duties. The company reported a 7.7% decrease in net sales for Q1 2025 compared to the previous year, impacted by foreign currency changes and a decline in Byte sales. Despite these challenges, Dentsply Sirona maintained its outlook for organic sales and adjusted EPS, emphasizing its commitment to long-term performance through transformational initiatives.